$130.35
▲ +0.0% Today
as of Jul 22, 16:49 ET
Last 30 days
Recent Press Releases & News
mixed
▲ 3
● 22
▼ 0
Gilead (GILD) Will Bring New HIV Data And A Merck Regimen To AIDS 2026
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Gilead Sciences Shares Fall After Downgrade From Leerink Partners
Overview
52-week range
$104
$157
49% of range
Avg surprise (last 3)
+3.3%
Avg reaction (last 2)
-0.9%
0% positive
Latest IV / EM
45%
EM ±2.7% · $133 · Jul 24
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $2.03 | $1.89 | +7.4% | +12.2% | -1.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $2.43 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $2.01 | $1.95 | +3.1% | — | — | earnings |
| Thu Apr 24, 2025 | Mar/2025 | $1.81 | $1.82 | -0.6% | — | -0.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $1.00 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $1.29 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-3.34 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $1.73 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.83 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$7.09 | $2.01 | -452.7% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | $1.45B | — | $1.57B | $1.50B | $1.54B | — | $1.57B | $1.54B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $2.59B | — | $3.33B | $2.47B | $2.24B | — | $888M | $2.64B |
| Net income | $2.02B | — | $3.05B | $1.96B | $1.31B | — | $1.25B | $1.61B |
| EPS (diluted) | $1.61 | — | $2.43 | $1.56 | $1.04 | — | $1.00 | $1.29 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | — | — | — | — | — | — | — |
| Inventory | $1.91B | $1.77B | $1.78B | $1.82B | $1.76B | $1.71B | $1.87B | $2.03B |
| Total current assets | $18.64B | $18.34B | $17.87B | $14.72B | $16.90B | $19.17B | $14.78B | $12.32B |
| Total assets | $56.28B | $59.02B | $58.53B | $55.72B | $56.43B | $58.99B | $54.52B | $53.58B |
| Long-term debt | $20.86B | $22.13B | $22.14B | $22.14B | $22.15B | $24.90B | $21.44B | $21.54B |
| Total liabilities | — | — | — | — | — | — | — | — |
| Total equity | $23.52B | $22.70B | $21.54B | $19.67B | $19.16B | $19.33B | $18.48B | $18.28B |